Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Ping An Biomedical Plans to Buy Three Tumor-Related Patents for USD 2 Million–2.5 Million

Ping An Biomedical Plans to Buy Three Tumor-Related Patents for USD 2 Million–2.5 Million

BitgetBitget2026/10/26 12:32
  • Ping An Biomedical signed a letter of intent to acquire three tumor-related medical technology patents from Future Biotechnology Group for USD 2 million–USD 2.5 million.
  • The planned acquisition would establish a core oncology and biotechnology intellectual property portfolio to support longer-term healthcare development.
  • No material near-term revenue is expected from the acquisition alone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ping An Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-112291), on October 26, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

JPMorgan Chief Global Strategist: Tech stock trading has entered a phase of volatility and uncertainty; investors should diversify their AI holdings

David Kelly, Chief Global Strategist at JPMorgan Asset Management, stated that as the artificial intelligence (AI) industry shows signs of entering a new phase characterized by increased volatility and rising technological uncertainty, investors should diversify their AI-related holdings.

智通财经•2026/11/17 04:11
JPMorgan Chief Global Strategist: Tech stock trading has entered a phase of volatility and uncertainty; investors should diversify their AI holdings

Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases

Jim Cramer called Intel his top stock pick, but its share price is down about 61% from its historical high. Intel lowered its Q4 revenue guidance to below $16.5 billion. CEO Pat Gelsinger recently bought 150,000 additional shares. Meanwhile, a shareholder lawsuit accuses the company of underestimating the weakness in the PC market.

智通财经•2026/11/17 03:51
Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases